Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122570 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| Hydrochloric Acid SCHEMBL9589944 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| Hydrochloric Acid SCHEMBL8596085 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| SCHEMBL24359844 | 0.81 | PTGS1 (0.41) | PTGS1SLC7A11ENPEPSLC7A5 | |
| SCHEMBL23408842 | 0.81 | SLC7A5 (0.43) | PTGS1SLC7A11ENPEPSLC7A5ANPEP | |
| SCHEMBL6535208 | 0.80 | PTGS1 (0.44) | PTGS1SLC7A11ENPEPSLC7A5ANPEP | |
| SCHEMBL5330308 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 | |
| SCHEMBL9384783 | 0.79 | PTGS1 (0.48) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL30606392 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 | |
| SCHEMBL13155620 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| EP-4619503-A1 | OPTIMIZED ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS AND USES THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| WO-2024107853-A1 | OPTIMIZED ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-05-23 | — | — | WO | claimed |
| CN-113204788-B | Fine granularity attribute matching privacy protection method | 广州大学 | 2023-06-16 | — | — | CN | claimed |
| CN-109477840-A | For non-destructively determining the method and system of Fowl Sex in ovum | 因欧沃私人有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| US-20260150129-A1 | Communication Method, Apparatus, and System | HUAWEI TECHNOLOGIES CO., LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260117695-A1 | EPIC Cycles for the EPIC Cycle Engine | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260002925-A1 | NANOPORE SYSTEMS AND METHODS FOR SINGLE-MOLECULE POLYMER PROFILING | UNIV GRONINGEN (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4619503-A1 | OPTIMIZED ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS AND USES THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120118841-A | Composition, induction method and application of chemical reprogramming induction functional ciRPE cells | 瓯江实验室 | 2025-06-10 | — | — | CN | disclosed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | disclosed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-1998055135-A1 | PROTECTIVE COMPOSITIONS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1998-12-10 | — | — | WO | disclosed |
| EP-0546063-A1 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004024-A2 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | PTGS1 4223/4885SLC7A11 1904/4885TSHR 403/4885 |
| US-20260150129-A1 | Communication Method, Apparatus, and System | STUB1, CBLC, CHRNA2 | PTGS1 4474/4885SLC7A11 1255/4885TSHR 2302/4885 |
| US-20260002925-A1 | NANOPORE SYSTEMS AND METHODS FOR SINGLE-MOLECULE POLYMER PROFILING | SLC9A2, SLC10A6, NUP210 | PTGS1 4013/4885SLC7A11 580/4885TSHR 1211/4885 |
| US-20260117695-A1 | EPIC Cycles for the EPIC Cycle Engine | CCNI, AXIN2, CTNNB1 | PTGS1 4688/4885SLC7A11 3665/4885TSHR 4184/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | PTGS1 4353/4885SLC7A11 2834/4885TSHR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.